George Wilding - Publications

Affiliations: 
University of Wisconsin, Madison, Madison, WI 
Area:
Toxicology, Oncology, Molecular Biology, Cell Biology
Website:
http://faculty.mdanderson.org/George_Wilding/Default.asp?SNID=2

257 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Basu HS, Wilganowski N, Robertson S, Reuben JM, Cohen EN, Zurita A, Ramachandran S, Xiao LC, Titus M, Wilding G. Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities. The Prostate. PMID 34170017 DOI: 10.1002/pros.24146  1
2018 Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, ... ... Wilding G, et al. A Festschrift in Honor of Edward M. Messing, MD, FACS. Bladder Cancer (Amsterdam, Netherlands). 4: S1-S43. PMID 30443561 DOI: 10.3233/BLC-189037  1
2018 Basu HS, Wilgonowski NL, Lieblich JL, Wu GT, Fokt I, Ramachandran S, Yu J, Titus M, Priebe W, Beebe DJ, Wilding G. Abstract 3846: A metabolic pathway targeted inhibitor for precision therapy of castrate-resistant prostate cancer Cancer Research. 78: 3846-3846. DOI: 10.1158/1538-7445.Am2018-3846  1
2017 Wong YN, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams SD, Fisch MJ, Cella D, Carducci MA, Wilding G. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clinical Genitourinary Cancer. PMID 29173976 DOI: 10.1016/J.Clgc.2017.10.001  1
2017 Engle JA, Traynor AM, Campbell TC, Wisinski KB, LoConte N, Liu G, Wilding G, Kolesar JM. Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 1078155217704989. PMID 28457192 DOI: 10.1177/1078155217704989  1
2017 Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28275168 DOI: 10.1158/1078-0432.CCR-16-2439  0.01
2016 Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood VE, Carducci M. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. British Journal of Cancer. 114: 986-94. PMID 27115568 DOI: 10.1038/Bjc.2016.72  1
2016 Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). PMID 26969090 DOI: 10.1016/S0140-6736(16)00559-6  1
2016 Kyriakopoulos CE, Heath EI, Eickhoff JC, Kolesar J, Yayehyirad M, Moll T, Wilding G, Liu G. A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Investigational New Drugs. PMID 26924129 DOI: 10.1007/S10637-016-0334-Y  1
2016 Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, ... ... Wilding G, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26903579 DOI: 10.1200/Jco.2015.64.2702  1
2016 Yu J, Weichmann AM, Craig A, Huang W, Church DR, Mehraein F, Parker LL, Beebe DJ, Wilding G, Basu HS. Abstract 4968: “Moonlighting Functions” of glycolytic enzymes relate to human prostate cancer invasion Cancer Research. 76: 4968-4968. DOI: 10.1158/1538-7445.Am2016-4968  1
2016 Carles J, Davis I, Bono JSd, Fizazi K, Gerritsen W, Rathkopf DE, Ryan CJ, Saad F, Steuber T, Wilding G, Park YC, Charnas R, Porre PD, Poppel HV. Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs) Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw372.24  1
2015 Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer : For submission to Investigational New Drugs. Investigational New Drugs. PMID 26666244 DOI: 10.1007/S10637-015-0314-7  1
2015 Mehraein-Ghomi F, Church DR, Schreiber CL, Weichmann AM, Basu HS, Wilding G. Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81). Genes & Cancer. 6: 428-444. PMID 26622945  1
2015 Chen Y, Rini BI, Motzer RJ, Dutcher JP, Rixe O, Wilding G, Stadler WM, Tarazi J, Garrett M, Pithavala YK. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Targeted Oncology. PMID 26400730 DOI: 10.1007/S11523-015-0389-2  1
2015 Carducci MA, Manola J, Nair SG, Liu G, Rousey S, Dutcher JP, Wilding G. Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). Clinical Genitourinary Cancer. PMID 26272427 DOI: 10.1016/J.Clgc.2015.07.002  1
2015 Huang SX, Yun BS, Ma M, Basu HS, Church DR, Ingenhorst G, Huang Y, Yang D, Lohman JR, Tang GL, Ju J, Liu T, Wilding G, Shen B. Leinamycin E1 acting as an anticancer prodrug activated by reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America. 112: 8278-83. PMID 26056295 DOI: 10.1073/Pnas.1506761112  1
2015 Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J, Liu G, Wilding G, Johnston S, Kolesar JM. Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 72: 958-65. PMID 25987691 DOI: 10.2146/Ajhp140591  1
2015 Haas N, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane C, Jewett MA, Wood L, Wood CG, Atkins MB, Dutcher JP, Wilding G, DiPaola R. Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases:results from ASSURE, ECOG2805. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25967143 DOI: 10.1158/1078-0432.Ccr-15-0215  1
2015 Huang W, Eickhoff JC, Mehraein-Ghomi F, Church DR, Wilding G, Basu HS. Expression of spermidine/spermine N(1) -acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. The Prostate. 75: 1150-9. PMID 25893668 DOI: 10.1002/Pros.22996  1
2015 Basu HS, Schrieber CL, Sperger JM, Naundorf M, Weichman AM, Mehraein-Ghomi F, Church DR, Lang JM, Wilding G. Abstract 2899: Mitophagy imparts enzalutamide resistance in prostate cancer Cancer Research. 75: 2899-2899. DOI: 10.1158/1538-7445.Am2015-2899  1
2014 DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, Wilding G. A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802. European Urology. PMID 25533418 DOI: 10.1016/J.Eururo.2014.12.010  1
2014 Wisinski KB, Ledesma WM, Kolesar J, Wilding G, Liu G, Douglas J, Traynor AM, Albertini M, Mulkerin D, Bailey HH. A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. PMID 24986793 DOI: 10.1177/1078155214541572  1
2014 McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3692-704. PMID 24850844 DOI: 10.1158/1078-0432.Ccr-14-0169  1
2014 Mehraein-Ghomi F, Kegel SJ, Church DR, Schmidt JS, Reuter QR, Saphner EL, Basu HS, Wilding G. Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression. The Prostate. 74: 792-803. PMID 24647988 DOI: 10.1002/Pros.22800  1
2014 Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Investigational New Drugs. 32: 323-9. PMID 24114123 DOI: 10.1007/S10637-013-0035-8  1
2014 Schelman WR, Mohammed TA, Traynor AM, Kolesar JM, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Investigational New Drugs. 32: 295-302. PMID 23860642 DOI: 10.1007/S10637-013-9999-7  1
2014 Wisinski KB, Cantu CA, Eickhoff JC, Osterby K, Tevaarwerk A, Liu G, Wilding G, Johnston S, Kolesar J. Cytochrome P450 interacting medication use in adult advanced solid tumor and phase I trial patients. Journal of Clinical Oncology. 32: 2591-2591. DOI: 10.1200/Jco.2014.32.15_Suppl.2591  1
2013 Madan RA, Stein WD, Wilkerson J, Dahut WL, Heery CR, Schlom J, Wilding G, DiPaola RS. Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 57. PMID 28137072 DOI: 10.1200/Jco.2013.31.6_Suppl.57  1
2013 Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev V, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, De Bono JS, et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: LBA8. PMID 28136933 DOI: 10.1200/Jco.2013.31.6_Suppl.Lba8  1
2013 Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. The Lancet. Oncology. 14: 1307-16. PMID 24211163 DOI: 10.1016/S1470-2045(13)70479-0  1
2013 Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, ... Wilding G, et al. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Investigational New Drugs. 31: 1539-46. PMID 24114121 DOI: 10.1007/S10637-013-0029-6  1
2013 Kolesar JM, Traynor AM, Holen KD, Hoang T, Seo S, Kim K, Alberti D, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH, Schelman WR. Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Cancer Chemotherapy and Pharmacology. 72: 661-7. PMID 23903894 DOI: 10.1007/S00280-013-2242-6  1
2013 Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, McNeel DG. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clinical Genitourinary Cancer. 11: 407-15. PMID 23835291 DOI: 10.1016/J.Clgc.2013.04.029  1
2013 Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T, Allen-Freda E, Mishra KK, Porro MG, Scher HI, Wilding G. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 72: 537-44. PMID 23820963 DOI: 10.1007/S00280-013-2224-8  1
2013 Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet. Oncology. 14: 882-92. PMID 23810788 DOI: 10.1016/S1470-2045(13)70240-7  1
2013 Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. Journal of Clinical Pharmacology. 53: 491-504. PMID 23553560 DOI: 10.1002/Jcph.73  1
2013 Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, et al. Intermittent versus continuous androgen deprivation in prostate cancer. The New England Journal of Medicine. 368: 1314-25. PMID 23550669 DOI: 10.1056/Nejmoa1212299  1
2013 Gee J, Bailey H, Kim K, Kolesar J, Havighurst T, Tutsch KD, See W, Cohen MB, Street N, Levan L, Jarrard D, Wilding G. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. The Prostate. 73: 970-8. PMID 23335089 DOI: 10.1002/Pros.22644  1
2013 Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urologic Oncology. 31: 581-8. PMID 21816640 DOI: 10.1016/J.Urolonc.2011.04.009  1
2013 Liu G, Chen YH, Kolesar J, Huang W, Dipaola R, Pins M, Carducci M, Stein M, Bubley GJ, Wilding G. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urologic Oncology. 31: 211-8. PMID 21784672 DOI: 10.1016/J.Urolonc.2011.01.002  1
2013 Cetnar J, Wilding G, McNeel D, LoConte NK, McFarland TA, Eickhoff J, Liu G. A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urologic Oncology. 31: 436-41. PMID 21481618 DOI: 10.1016/J.Urolonc.2011.02.007  1
2013 Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S. Hereditary and sporadic cancers respond to niraparib Cancer Discovery. 3. DOI: 10.1158/2159-8290.Cd-Rw2013-148  1
2013 Mahalingam D, Cetnar J, Wilding G, Denmeade S, Sarantopoulos J, Kurman M, Carducci M. Abstract B244: A first-in-human phase 1 clinical study of G-202, a thapsigargin-based Prostate-Specific Membrane Antigen (PSMA) activated prodrug, in patients with advanced solid tumors. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B244  1
2012 Tangen CM, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Akdas A, Small EJ, Dawson NA, Donnelly BJ, Venner P, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4. PMID 28140795 DOI: 10.1200/Jco.2012.30.15_Suppl.4  1
2012 Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). The Journal of Urology. 188: 1164-9. PMID 22921015 DOI: 10.1016/J.Juro.2012.06.046  1
2012 Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Science Translational Medicine. 4: 140ra86. PMID 22745436 DOI: 10.1126/Scitranslmed.3003886  1
2012 Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clinical Genitourinary Cancer. 10: 232-8. PMID 22695254 DOI: 10.1016/J.Clgc.2012.05.001  1
2012 Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1371-7. PMID 22430274 DOI: 10.1200/Jco.2011.36.4133  1
2012 Liu G, Chen YH, Dipaola R, Carducci M, Wilding G. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clinical Genitourinary Cancer. 10: 99-105. PMID 22386239 DOI: 10.1016/J.Clgc.2012.01.009  1
2012 McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, Liu G. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunology, Immunotherapy : Cii. 61: 1137-47. PMID 22210552 DOI: 10.1007/S00262-011-1193-1  1
2012 Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Maneval EC, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 23: 688-94. PMID 21821830 DOI: 10.1093/Annonc/Mdr349  1
2012 Holen K, DiPaola R, Liu G, Tan AR, Wilding G, Hsu K, Agrawal N, Chen C, Xue L, Rosenberg E, Stein M. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Investigational New Drugs. 30: 1088-95. PMID 21424701 DOI: 10.1007/S10637-011-9653-1  1
2012 Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Medical Oncology (Northwood, London, England). 29: 761-7. PMID 21298497 DOI: 10.1007/S12032-011-9829-8  1
2012 Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Investigational New Drugs. 30: 1039-45. PMID 21225315 DOI: 10.1007/S10637-010-9629-6  1
2012 Bruce JY, Eickhoff J, Pili R, Logan T, Carducci M, Arnott J, Treston A, Wilding G, Liu G. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Investigational New Drugs. 30: 794-802. PMID 21174224 DOI: 10.1007/S10637-010-9618-9  1
2012 Deming DA, Schelman WR, Lubner SJ, Mulkerin D, LoConte NK, Fioravanti S, Greten T, Eickhoff JC, Kolesar J, Compton K, Doyle LA, Wilding G, Duffy AG, Liu G. A phase I study of selumetinib (AZD6244/ARRY-142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC). Journal of Clinical Oncology. 30: 3103-3103. DOI: 10.1200/Jco.2012.30.15_Suppl.3103  1
2012 LoConte NK, Tevaarwerk A, Kolesar J, Holen KD, Lubner SJ, Mulkerin D, Schelman WR, Razak ARA, Siu LL, Eickhoff JC, Carmichael L, Wilding G, Ivy SP, Liu G. A phase I study of the gamma-secretase inhibitor RO4929097 and capecitabine in refractory solid tumors. Journal of Clinical Oncology. 30: 3101-3101. DOI: 10.1200/Jco.2012.30.15_Suppl.3101  1
2012 Schmidt J, Kegel S, Mehraein-Ghomi F, Saphner E, Reuter Q, Church D, Hoffmann FM, Basu HS, Wilding G. Abstract 2844: Inhibiting androgen receptor and JunD protein interaction to prevent prostate cancer progression Cancer Research. 72: 2844-2844. DOI: 10.1158/1538-7445.Am2012-2844  1
2012 Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, DeMarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy (Science Translational Medicine) Science Translational Medicine. 4. DOI: 10.1126/Scitranslmed.3004546  1
2011 Lang JM, Eickhoff JC, Binkley NC, Staab MJ, Liu G, Wilding G, McNeel DG. Randomized phase II trial evaluating different schedules of zoledronic acid administration on bone mineral density in patients with stage D prostate cancer beginning androgen deprivation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4643. PMID 28023932 DOI: 10.1200/Jco.2011.29.15_Suppl.4643  1
2011 Harrison MR, Jeraj R, Hammers HJ, Stein MN, Andrei A, Perlman S, Kolesar J, Marnocha RM, Alberti DB, Wilding G, Liu G. Phase I pharmacodynamic trial of sequential sunitinib (SU) with bevacizumab (bev) in patients with renal cell carcinoma (mRCC) and other advanced solid malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13503. PMID 28022895 DOI: 10.1200/jco.2011.29.15_suppl.e13503  1
2011 Schelman WR, Sandhu SK, Moreno Garcia V, Wilding G, Sun L, Toniatti C, Stroh M, Kreischer N, Carpenter CL, Molife LR, Kaye SB, De Bono JS, Wenham RM. First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3102. PMID 28022756 DOI: 10.1200/jco.2011.29.15_suppl.3102  1
2011 Traynor AM, Kolesar J, Marnocha RM, Eikhoff JC, Alberti DB, Takebe N, Wilding G, Liu G, Schelman WR. A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients (pts) with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3040. PMID 28022615 DOI: 10.1200/jco.2011.29.15_suppl.3040  1
2011 Stein MN, Khan I, Hussain M, Liu G, Wilding G, Posadas EM, Stadler WM, Jeyamohan C, Eddy S, DiPaola RS. Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastatic prostate cancer (ADMPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 137. PMID 27968504 DOI: 10.1200/jco.2011.29.7_suppl.137  1
2011 Lang JM, Staab MJ, Liu G, Wilding G, McNeel DG. Phase I dose-escalation trial of tremelimumab in combination with bicalutamide in patients with recurrent prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 174. PMID 27968439 DOI: 10.1200/Jco.2011.29.7_Suppl.174  1
2011 Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Martell B, Hariharan S, Figlin RA. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: LBA308. PMID 27968383 DOI: 10.1200/jco.2011.29.7_suppl.lba308  1
2011 Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, Simoncic U, Eickhoff J, Carmichael L, Chao B, Marnocha R, Ivy P, Wilding G. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7634-44. PMID 22038997 DOI: 10.1158/1078-0432.Ccr-11-1677  1
2011 Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, Liu G, Eickhoff JC, McNeel DG, Malkovsky M. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunology, Immunotherapy : Cii. 60: 1447-60. PMID 21647691 DOI: 10.1007/S00262-011-1049-8  1
2011 Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 77: 1166-71. PMID 21539969 DOI: 10.1016/J.Urology.2011.01.006  1
2011 Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. Experimental and Therapeutic Medicine. 2: 119-123. PMID 21373381 DOI: 10.3892/Etm.2010.165  1
2011 Heath EI, Blumenschein GR, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology. 68: 703-12. PMID 21140147 DOI: 10.1007/S00280-010-1536-1  1
2011 Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MJ, Slovin SF, Sasaki Y, Takahashi S, Ozono S, Fung NK, Cheng S, Gan J, Gottardis M, Obermeier MT, ... ... Wilding G, et al. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 880-7. PMID 21131556 DOI: 10.1158/1078-0432.Ccr-10-2955  1
2011 Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, et al. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors Annals of Oncology. 22: 1413-1419. PMID 21131369 DOI: 10.1093/Annonc/Mdq599  1
2011 Basu HS, Mahlum A, Mehraein-Ghomi F, Kegel SJ, Guo S, Peters NR, Wilding G. Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemotherapy and Pharmacology. 67: 705-15. PMID 20512578 DOI: 10.1007/S00280-010-1364-3  1
2011 Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs. 29: 1465-74. PMID 20499131 DOI: 10.1007/S10637-010-9455-X  1
2011 Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK, Vasist LS, Bowen CJ, Hodge JP, Dar MM, Ho PT. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemotherapy and Pharmacology. 67: 447-54. PMID 20461380 DOI: 10.1007/S00280-010-1346-5  1
2011 Kolesar J, Brundage RC, Pomplun M, Alberti D, Holen K, Traynor A, Ivy P, Wilding G. Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients. Cancer Chemotherapy and Pharmacology. 67: 393-400. PMID 20440618 DOI: 10.1007/S00280-010-1331-Z  1
2011 Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 67: 305-14. PMID 20386909 DOI: 10.1007/S00280-010-1318-9  1
2011 Traynor AM, Thomas JP, Ramanathan RK, Mody TD, Alberti D, Wilding G, Bailey HH. Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. Investigational New Drugs. 29: 316-22. PMID 19997959 DOI: 10.1007/S10637-009-9364-Z  1
2011 Schelman WR, Liu G, Wilding G, Morris T, Phung D, Dreicer R. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Investigational New Drugs. 29: 118-25. PMID 19763400 DOI: 10.1007/S10637-009-9318-5  1
2011 Kolesar JM, Lau E, Seo S, Eickhoff J, Kim K, Traynor A, Bailey H, Wilding G, Schelman W. Abstract 4396: Evaluation of gene expression and transcriptional activation in patients treated with vorinostat: Cancer Research. 71: 4396-4396. DOI: 10.1158/1538-7445.Am2011-4396  1
2011 Kegel S, Mehraein-Ghomi F, Reuter Q, Schmidt J, Church D, Hoffmann FM, Basu H, Wilding G. Abstract 2583: Targeting a novel pathway for prostate cancer therapy Cancer Research. 71: 2583-2583. DOI: 10.1158/1538-7445.Am2011-2583  1
2011 Mehraein-Ghomi F, Basu HS, Miyamoto S, Wilding G. Abstract 2165: Identification of a novel pathway of castrate resistant prostate cancer (CRPCa) growth Cancer Research. 71: 2165-2165. DOI: 10.1158/1538-7445.Am2011-2165  1
2011 Wenham R, Wilding G, Baird R, Sun L, Toniatti C, Stroh M, Carpenter C, de-Bono J, Sandhu S, Schelman W. First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers Gynecologic Oncology. 120. DOI: 10.1016/J.Ygyno.2010.12.015  1
2010 Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. Journal of the National Cancer Institute. 102: 1536-46. PMID 20858887 DOI: 10.1093/Jnci/Djq364  1
2010 Mehraein-Ghomi F, Basu HS, Church DR, Hoffmann FM, Wilding G. Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. Cancer Research. 70: 4560-8. PMID 20460526 DOI: 10.1158/0008-5472.Can-09-3596  1
2010 DiPaola RS, Chen YH, Stein M, Vaughn D, Patrick-Miller L, Carducci M, Roth B, White E, Wilding G. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. Journal of Translational Medicine. 8: 20. PMID 20178647 DOI: 10.1186/1479-5876-8-20  1
2010 Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 66: 973-80. PMID 20127092 DOI: 10.1007/S00280-010-1250-Z  1
2010 LoConte NK, Smith M, Alberti D, Bozeman J, Cleary JF, Setala AN, Wodtke G, Wilding G, Holen KD. Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. Cancer Chemotherapy and Pharmacology. 65: 775-80. PMID 19649630 DOI: 10.1007/S00280-009-1084-8  1
2010 Traynor AM, Gordon MS, Alberti D, Mendelson DS, Munsey MS, Wilding G, Gammans RE, Read WL. A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Investigational New Drugs. 28: 509-15. PMID 19434370 DOI: 10.1007/S10637-009-9264-2  1
2010 Chow SL, Lin Y, LoConte NK, Royds RB, Nekrassova TG, Ivy SP, Mauer J, Wilding G, Stoller R, Egorin MJ. Enrollment of and toxicity in patients 70 years and older on CTEP/NCI-sponsored, single-agent phase I studies from 1980 to 2005. Journal of Clinical Oncology. 28: 9119-9119. DOI: 10.1200/Jco.2010.28.15_Suppl.9119  1
2010 Garcia-Manero G, Chuah C, Wilding G, Chang J, Verstovsek S, Faderl S, Kantarjian HM, Ethirajulu K, Zhu J. Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies Blood. 116: 3292-3292. DOI: 10.1182/Blood.V116.21.3292.3292  0.01
2010 Huang W, Jarrard D, Ritter M, Waknitz M, Straus J, Wilding G. Abstract 4630: Seminal AMACR protein: a non-invasive test in the detection of prostate cancer Cancer Research. 70: 4630-4630. DOI: 10.1158/1538-7445.Am10-4630  1
2009 Yu E, Massard C, Gross M, Wilding G, Posadas E, Culine S, Carducci MA, Trudel G, Paliwal P, Sternberg C. A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5147. PMID 27964443 DOI: 10.1200/jco.2009.27.15_suppl.5147  1
2009 Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte N, Kim ST, Chao R, Wilding G. Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e14509. PMID 27963544 DOI: 10.1200/jco.2009.27.15_suppl.e14509  1
2009 Vinson J, Mathew P, Beer TM, Carducci MA, Oh W, Small E, Wilding G, Higano C, Hussain M, Scher HI. Prostate cancer clinical trials consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e16065. PMID 27963069 DOI: 10.1200/jco.2009.27.15_suppl.e16065  1
2009 Rixe O, Dutcher J, Motzer R, Wilding G, Stadler WM, Garrett M, Pithavala Y, Kim S, Tarazi J, Rini BI. Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5045. PMID 27962952 DOI: 10.1200/jco.2009.27.15_suppl.5045  1
2009 Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabrò F, Cheng S, Trudel GC, Paliwal P, Sternberg CN. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7421-8. PMID 19920114 DOI: 10.1158/1078-0432.Ccr-09-1691  1
2009 Burris HA, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, Fleming RA, Smith DA, Pandite L, Spector N, Wilding G. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6702-8. PMID 19825948 DOI: 10.1158/1078-0432.Ccr-09-0369  1
2009 Basu HS, Thompson TA, Church DR, Clower CC, Mehraein-Ghomi F, Amlong CA, Martin CT, Woster PM, Lindstrom MJ, Wilding G. A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Research. 69: 7689-95. PMID 19773450 DOI: 10.1158/0008-5472.Can-08-2472  1
2009 Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4462-8. PMID 19652060 DOI: 10.1200/Jco.2008.21.7034  1
2009 McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4047-54. PMID 19636017 DOI: 10.1200/Jco.2008.19.9968  1
2009 Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, Wilding G. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. 115: 4090-5. PMID 19536901 DOI: 10.1002/Cncr.24467  1
2009 Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3584-90. PMID 19487381 DOI: 10.1200/Jco.2008.20.1293  1
2009 Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2450-6. PMID 19380444 DOI: 10.1200/Jco.2008.19.9810  1
2009 Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3172-6. PMID 19366825 DOI: 10.1158/1078-0432.Ccr-08-2985  1
2009 Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM, Weeks HR, Wilding G, Espinoza-Delgado I, Schiller JH. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 522-6. PMID 19347984 DOI: 10.1097/Jto.0B013E3181952478  1
2009 Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1460-5. PMID 19228747 DOI: 10.1158/1078-0432.Ccr-08-1599  1
2009 Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SE, Ryan C, Logothetis C, et al. Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research Clinical Genitourinary Cancer. 7: 51-57. PMID 19213669 DOI: 10.3816/Cgc.2009.N.009  1
2009 Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, Fayyad R, Figlin RA. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clinical Genitourinary Cancer. 7: 28-33. PMID 19213665 DOI: 10.3816/Cgc.2009.N.005  1
2009 Mulkerin D, Loconte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G. A phase I study of an oral simulated FOLFOX with high dose capecitabine Investigational New Drugs. 27: 461-468. PMID 19129971 DOI: 10.1007/S10637-008-9210-8  1
2009 Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 63: 1147-56. PMID 19082825 DOI: 10.1007/S00280-008-0890-8  1
2009 Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A, Ivy P, Wilding G. Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemotherapy and Pharmacology. 64: 79-86. PMID 18941749 DOI: 10.1007/S00280-008-0845-0  1
2009 Attia S, Morgan-Meadows S, Holen KD, Bailey HH, Eickhoff JC, Schelman WR, Traynor AM, Mulkerin DL, Campbell TC, McFarland TA, Huie MS, Cleary JF, Tevaarwerk AJ, Alberti DB, Wilding G, et al. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 64: 45-51. PMID 18841362 DOI: 10.1007/S00280-008-0844-1  1
2009 Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urologic Oncology. 27: 496-501. PMID 18639470 DOI: 10.1016/J.Urolonc.2008.05.004  1
2009 Dutcher J, Garrett M, Wilding G, Stadler WM, Pithavala Y, Kim S, Tarazi J, Rixe O, Rini BI. Abstract B213: Pharmacokinetics (PK) and efficacy of axitinib in patients (pts) with sorafenib‐refractory metastatic renal cell carcinoma (mRCC) Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B213  1
2008 Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte NK, Kim ST, Chao R, Wilding G. Phase I study of sunitinib in combination with carboplatin (C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3565. PMID 27949637 DOI: 10.1200/jco.2008.26.15_suppl.3565  1
2008 Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Hudes GR, Cheng S, Paliwal P, Sternberg CN. Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5156. PMID 27948244 DOI: 10.1200/jco.2008.26.15_suppl.5156  1
2008 Ricart AD, Tolcher AW, Liu G, Holen K, Schwartz G, Albertini M, Weiss G, Yazji S, Ng C, Wilding G. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7924-9. PMID 19047123 DOI: 10.1158/1078-0432.Ccr-08-0378  1
2008 Lardy H, Marwah A, Zhong W, Moore R, Marwah P, Thompson T, Wilding G. A test of rats' tolerance for 3β-acetoxyandrosta-1,5-dien-17-one ethylene ketal (ADEK), a new anti-androgen Journal of Steroid Biochemistry and Molecular Biology. 111: 60-65. PMID 18539452 DOI: 10.1016/J.Jsbmb.2007.11.008  1
2008 Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer. 112: 2671-5. PMID 18459175 DOI: 10.1002/Cncr.23503  1
2008 Liu G, Kolesar J, McNeel DG, Leith C, Schell K, Eickhoff J, Lee F, Traynor A, Marnocha R, Alberti D, Zwiebel J, Wilding G. A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2732-9. PMID 18451239 DOI: 10.1158/1078-0432.Ccr-07-1490  1
2008 Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M, Alberti D, Staab MJ, Horvath D, Straus J, Marnocha R, et al. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2437-43. PMID 18413835 DOI: 10.1158/1078-0432.Ccr-07-4274  1
2008 Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, Wilding G. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. The Prostate. 68: 924-34. PMID 18386285 DOI: 10.1002/Pros.20737  1
2008 LoConte NK, Thomas JP, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, Kolesar J. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 63: 109-15. PMID 18322686 DOI: 10.1007/S00280-008-0719-5  1
2008 Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, ... ... Wilding G, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1148-59. PMID 18309951 DOI: 10.1200/Jco.2007.12.4487  1
2008 Schelman W, Morgan-Meadows S, Bailey H, Holen K, Thomas JP, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 62: 727-33. PMID 18172649 DOI: 10.1007/S00280-007-0656-8  1
2008 Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. Journal of Inorganic Biochemistry. 102: 693-8. PMID 18061679 DOI: 10.1016/J.Jinorgbio.2007.10.013  1
2008 Hutson PR, Oettel K, Douglas J, Ritter M, Messing E, Staab MJ, Alberti D, Horvath D, Wilding G. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemotherapy and Pharmacology. 62: 373-7. PMID 17922273 DOI: 10.1007/S00280-007-0613-6  1
2007 Lalich M, McNeel DG, Wilding G, Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Investigation. 25: 785-94. PMID 18058475 DOI: 10.1080/07357900701522588  1
2007 Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The Lancet. Oncology. 8: 975-84. PMID 17959415 DOI: 10.1016/S1470-2045(07)70285-1  1
2007 Aziz MH, Manoharan HT, Church DR, Dreckschmidt NE, Zhong W, Oberley TD, Wilding G, Verma AK. Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Research. 67: 8828-38. PMID 17875724 DOI: 10.1158/0008-5472.Can-07-1604  1
2007 Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G. Sunitinib efficacy against advanced renal cell carcinoma. The Journal of Urology. 178: 1883-7. PMID 17868732 DOI: 10.1016/J.Juro.2007.07.030  1
2007 Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. Bju International. 100: 765-9. PMID 17822457 DOI: 10.1111/J.1464-410X.2007.07121.X  1
2007 Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer. 110: 759-63. PMID 17594721 DOI: 10.1002/Cncr.22839  1
2007 Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 110: 556-63. PMID 17577218 DOI: 10.1002/Cncr.22811  1
2007 Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3623-9. PMID 17510207 DOI: 10.1158/1078-0432.Ccr-07-0158  1
2007 Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. The Journal of Urology. 177: 1777-81. PMID 17437819 DOI: 10.1016/J.Juro.2007.01.028  1
2007 Zhang D, Pier T, McNeel DG, Wilding G, Friedl A. Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study. Investigational New Drugs. 25: 49-55. PMID 17001523 DOI: 10.1007/S10637-006-9013-8  1
2007 Attia S, Eickhoff J, Wilding G, Blank J, Rezazadeh H, Shevrin D, Glode M, Jumonville A, Eastman M, Liu G. Randomized phase II trial of docetaxel, with or without doxercalciferol, in advanced, androgen-independent prostate cancer Journal of Clinical Oncology. 25: 5119-5119. DOI: 10.1200/Jco.2007.25.18_Suppl.5119  1
2007 Stein MN, Tan A, Taber K, Fernandez R, Agrawal NG, Vandendries E, Hsu K, Walker A, Holen K, Wilding G. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in patients with solid tumors Journal of Clinical Oncology. 25: 2548-2548. DOI: 10.1200/Jco.2007.25.18_Suppl.2548  1
2006 Lalich M, Wilding G, Kolesar J, McNeel DG, Schell K, Leith C, Chappell R, Marnocha R, Alberti D, Liu G. A phase I study of antisense Bcl-2 oligonucleotide (G3139) in combination with carboplatin (C) and paclitaxel (T) in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 13006. PMID 27955410 DOI: 10.1200/Jco.2006.24.18_Suppl.13006  1
2006 Chang JE, Morgan Meadows S, Traynor A, Kolesar J, Marnocha R, Lee F, Eickoff J, Beth E, Binger K, Wilding G. A phase I study of triapine in combination with doxorubicin in refractory tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 13168. PMID 27954315 DOI: 10.1200/Jco.2006.24.18_Suppl.13168  1
2006 Stein MN, Rubin EH, Scott PD, Fernandez R, Agrawal NG, Hsu K, Walker A, Holen K, Wilding G. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2001. PMID 27952777 DOI: 10.1200/Jco.2006.24.18_Suppl.2001  1
2006 Attia S, Wilding G. Novel antioxidant technology for prostate cancer chemoprevention and treatment. Expert Opinion On Therapeutic Patents. 16: 1255-67. PMID 20144058 DOI: 10.1517/13543776.16.9.1255  1
2006 Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3984-90. PMID 16921051 DOI: 10.1200/Jco.2006.06.4246  1
2006 Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. The Journal of Urology. 176: 500-4. PMID 16813878 DOI: 10.1016/J.Juro.2006.03.061  1
2006 Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. Jama. 295: 2516-24. PMID 16757724 DOI: 10.1001/Jama.295.21.2516  1
2006 Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. The Lancet. Oncology. 7: 472-9. PMID 16750497 DOI: 10.1016/S1470-2045(06)70700-8  1
2006 Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, Ummersen Lv, Yu DC, Aimi J, Ando D, Kirn D, Wilding G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Molecular Therapy. 14: 107-117. PMID 16690359 DOI: 10.1016/J.Ymthe.2006.02.011  1
2006 Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS. Phase II clinical trial design: Methods in translational research from the genitourinary committee at the Eastern Cooperative Oncology Group Clinical Cancer Research. 12: 1966-1969. PMID 16609005 DOI: 10.1158/1078-0432.Ccr-05-1136  1
2006 Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 16-24. PMID 16330672 DOI: 10.1200/Jco.2005.02.2574  1
2006 Huie M, Oettel K, Ummersen LV, Kyung MK, Zhang Y, Staab MJ, Horvath D, Marnocha R, Douglas J, Drezen A, Alberti D, Wilding G. Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma Investigational New Drugs. 24: 255-260. PMID 16205854 DOI: 10.1007/S10637-005-3903-Z  1
2006 Meadows SM, Ummersen LV, Brandon H, Oliver K, Houston M, Eickhoff J, Wilding G. A dose escalation trial of fixed dose gemcitabine and capecitabine Journal of Clinical Oncology. 24: 12026-12026. DOI: 10.1200/Jco.2006.24.18_Suppl.12026  1
2005 Liu G, Dreicer R, Hou J, Chen Y, Wilding G. Tolerability profile of ZD4054 is consistent with the effects of endothelin A receptor-specific antagonism. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4628. PMID 27947004 DOI: 10.1200/jco.2005.23.16_suppl.4628  1
2005 Hegeman RB, Mulkerin D, Thomas J, Alberti D, Binger K, Marnocha R, Kolesar J, Wilding G. Phase I study of oxaliplatin in combination with 5-fluorouracil (5-FU), leucovorin (LV) and capecitabine (ORAL FOLFOX-6) in patients with advanced or metastatic solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2058. PMID 27946895 DOI: 10.1200/Jco.2005.23.16_Suppl.2058  1
2005 Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK, Bowen CJ, Williams DD, Dar MM, Ho PT. Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2010. PMID 27946825 DOI: 10.1200/jco.2005.23.16_suppl.2010  1
2005 Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, Bolte O, Steinfeldt H, Reich SD, Motzer R. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4509. PMID 27946522 DOI: 10.1200/jco.2005.23.16_suppl.4509  1
2005 Dubey S, Hutson P, Alberti D, Arzoomanian R, Binger K, Volkman J, Feierabend C, Wilding G, Schiller JH. Phase I study of docetaxel and topotecan in patients with advanced malignancies. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 11: 131-8. PMID 16595064 DOI: 10.1191/1078155205Jp161Oa  1
2005 Zlotocha S, Staab MJ, Horvath D, Straus J, Dobratz J, Oliver K, Wasielewski S, Alberti D, Liu G, Wilding G, Eickhoff J, McNeel DG. A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. Clinical Genitourinary Cancer. 4: 215-8. PMID 16425992 DOI: 10.3816/Cgc.2005.N.036  1
2005 Huie M, Carducci MA, Liu G, Wilding G, Marnocha R, Izquierda M, Thomas J. Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors. American Journal of Clinical Oncology. 28: 613-617. PMID 16317274 DOI: 10.1097/01.Coc.0000171281.13541.90  1
2005 McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7851-60. PMID 16278408 DOI: 10.1158/1078-0432.Ccr-05-0262  1
2005 Dutcher JP, Leon L, Manola J, Friedland DM, Roth B, Wilding G. Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study Cancer. 104: 2392-2399. PMID 16222691 DOI: 10.1002/cncr.21473  1
2005 Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6625-33. PMID 16166441 DOI: 10.1158/1078-0432.Ccr-05-0440  1
2005 Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5464-73. PMID 16027440 DOI: 10.1200/Jco.2005.04.143  1
2005 Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5474-83. PMID 16027439 DOI: 10.1200/Jco.2005.04.192  1
2005 Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3410-6. PMID 15867242 DOI: 10.1158/1078-0432.Ccr-04-2068  1
2005 Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. The Prostate. 63: 155-68. PMID 15486991 DOI: 10.1002/Pros.20172  1
2005 Holen KD, Belani CP, Wilding G, Ramalingam S, Heideman JL, Ramanathan RK, Bowen CJ, Williams DD, Hodge JP, Dar MM. Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor Journal of Clinical Oncology. 23: 2000-2000. DOI: 10.1200/Jco.2006.24.18_Suppl.2000  1
2005 Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukowski RM, George DJ, Kim ST, Baum CM. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) Journal of Clinical Oncology. 23: 4508-4508. DOI: 10.1200/Jco.2005.23.16_Suppl.4508  1
2005 Kibei AS, Kattan MW, Picus J, Dreicer R, Klein EA, Wilding G, Jarrard DF, Roth B, Cookson MS, Petrylak DP, Ghatta G, Nelson JB, Beer TM, Dipaola R, Partin AW, et al. 1589: Adjuvant Weekly Docetaxel for High-Risk Prostate Cancer Patients After Radical Prostatectomy The Journal of Urology. 173: 222-222. DOI: 10.1016/S0022-5347(18)33781-9  1
2004 Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Zhu J, Kim ST, Baum C. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4500. PMID 28016015 DOI: 10.1200/jco.2004.22.14_suppl.4500  1
2004 Chu QS, Holen KD, Rowinsky EK, Wilding G, Volkman JL, Orr JB, Williams DD, Hodge JP, Sabry J. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2078. PMID 28015702 DOI: 10.1200/jco.2004.22.14_suppl.2078  1
2004 Holen KD, Syed S, Hannah AL, Binger K, Wood L, Zhou Y, Cropp GF, Johnson RG, Rowinsky E, Wilding G. Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2024. PMID 28015590 DOI: 10.1200/Jco.2004.22.14_Suppl.2024  1
2004 Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Pithavala YK, McShane TM, Steinfeldt HM, Reich SD, Wilding G. Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2503. PMID 28015008 DOI: 10.1200/jco.2004.22.14_suppl.2503  1
2004 Pandite L, Burris HA, Jones S, Wilding G, Taylor C, Versola MJ, Smith DA, Stead A, Koch KM, Spector NL. A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3179. PMID 28014929 DOI: 10.1200/jco.2004.22.14_suppl.3179  1
2004 Hegeman RB, Liu G, Wilding G, McNeel DG. Newer therapies in advanced prostate cancer. Clinical Prostate Cancer. 3: 150-6. PMID 15636681 DOI: 10.3816/Cgc.2004.N.025  1
2004 Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7450-6. PMID 15569974 DOI: 10.1158/1078-0432.Ccr-03-0406  1
2004 Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 101: 2202-8. PMID 15484217 DOI: 10.1002/cncr.20655  1
2004 Schulz CA, Mehta MP, Badie B, McGinn CJ, Robins HI, Hayes L, Chappell R, Volkman J, Binger K, Arzoomanian R, Simon K, Alberti D, Feierabend C, Tutsch KD, Kunugi KA, ... Wilding G, et al. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. International Journal of Radiation Oncology, Biology, Physics. 59: 1107-15. PMID 15234045 DOI: 10.1016/J.Ijrobp.2003.12.007  1
2004 Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemotherapy and Pharmacology. 54: 368-76. PMID 15205914 DOI: 10.1007/S00280-004-0788-Z  1
2004 Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2122-32. PMID 15169798 DOI: 10.1200/Jco.2004.08.083  1
2004 Forouzannia A, Schiller J, Berlin J, Hutson P, Boothman D, Storer B, Wilding G, Mehta M. A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies Lung Cancer. 44: 111-119. PMID 15013589 DOI: 10.1016/J.Lungcan.2003.10.005  0.01
2004 Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim KM, Wilding G. A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer Clinical Cancer Research. 10: 924-928. PMID 14871968 DOI: 10.1158/1078-0432.Ccr-03-0050  1
2004 Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G. Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 909-15. PMID 14871966 DOI: 10.1158/1078-0432.Ccr-0981-3  1
2004 Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, ... ... Wilding G, et al. Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group Journal of Clinical Oncology. 22: 537-556. PMID 14752077 DOI: 10.1200/Jco.2004.07.099  1
2004 Wilding G, King D, Tutsch K, Pomplun M, Feierabend C, Alberti D, Arzoomanian R. Phase I trial of the polyamine analog N1, N 14-diethylhomospermine (DEHSPM) in patients with advanced solid tumors Investigational New Drugs. 22: 131-138. PMID 14739661 DOI: 10.1023/B:Drug.0000011789.79368.Ae  1
2004 Pandite L, Burris HA, Jones S, Wilding G, Taylor C, Versola MJ, Smith DA, Stead A, Koch KM, Spector NL. A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors Journal of Clinical Oncology. 22: 3179-3179. DOI: 10.1200/Jco.2004.22.90140.3179  1
2004 Versola M, Burris HA, Jones S, Wilding G, Taylor C, Pandite L, Smith DA, Stead A, Spector NL. Clinical activity of GW572016 in EGF10003 in patients with solid tumors Journal of Clinical Oncology. 22: 3047-3047. DOI: 10.1200/Jco.2004.22.90140.3047  1
2004 Chu QS, Holen KD, Rowinsky EK, Wilding G, Volkman JL, Orr JB, Williams DD, Hodge JP, Sabry J. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days Journal of Clinical Oncology. 22: 2078-2078. DOI: 10.1200/Jco.2004.22.90140.2078  1
2003 Liu G, Oettel K, Bailey H, Ummersen LV, Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh H, McGovern J, Robinson E, DeMets D, Wilding G. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Investigational New Drugs. 21: 367-72. PMID 14578686 DOI: 10.1023/A:1025437115182  1
2003 Frydman B, Blokhin AV, Brummel S, Wilding G, Maxuitenko Y, Sarkar A, Bhattacharya S, Church D, Reddy VK, Kink JA, Marton LJ, Valasinas aA, Basu HS. Cyclopropane-containing polyamine analogues are efficient growth inhibitors of a human prostate tumor xenograft in nude mice. Journal of Medicinal Chemistry. 46: 4586-4600. PMID 14521420 DOI: 10.1021/Jm030175U  1
2003 Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R, Alberti D, Binger K, Feierabend C, Volkman J, Ellingen S, Black S, Pomplun M, Wilding G, Bailey H. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemotherapy and Pharmacology. 52: 361-6. PMID 12904896 DOI: 10.1007/S00280-003-0684-Y  1
2003 Stadler W, Wilding G. Angiogenesis inhibitors in genitourinary cancers Critical Reviews in Oncology Hematology. 46: 41-47. PMID 12850526 DOI: 10.1016/S1040-8428(03)00063-5  0.01
2003 Liu G, Bailey HH, Arzoomanian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, Thomas JP. Gemcitabine, Paclitaxel, and piritrexim: a phase I study. American Journal of Clinical Oncology. 26: 280-4. PMID 12796601 DOI: 10.1097/01.Coc.0000081607.16287.6F  1
2003 Dreicer R, Manola J, Schneider DJ, Schwerkoske JF, George CS, Roth BJ, Wilding G. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer. 97: 2743-7. PMID 12767086 DOI: 10.1002/cncr.11413  1
2003 Bauer JA, Thompson TA, Church DR, Ariazi EA, Wilding G. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2. The Prostate. 55: 159-67. PMID 12692781 DOI: 10.1002/Pros.10219  1
2003 Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1214-22. PMID 12663707 DOI: 10.1200/Jco.2003.02.005  1
2003 Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 223-31. PMID 12525513 DOI: 10.1200/Jco.2003.12.120  1
2002 Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemotherapy and Pharmacology. 50: 465-72. PMID 12451473 DOI: 10.1007/S00280-002-0527-2  1
2002 Roth BJ, Manola J, Dreicer R, Graham D, Wilding G. Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): A phase II trial of the Eastern Cooperative Oncology Group Investigational New Drugs. 20: 425-429. PMID 12448661 DOI: 10.1023/A:1020675017737  1
2002 Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G. Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. Investigational New Drugs. 20: 377-82. PMID 12448654 DOI: 10.1023/A:1020673928704  1
2002 Vaughn DJ, Manola J, Dreicer R, See W, Levitt R, Wilding G. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer. 95: 1022-7. PMID 12209686 DOI: 10.1002/cncr.10782  1
2002 Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized Study of Three Different Doses of Suramin Administered With a Fixed Dosing Schedule in Patients With Advanced Prostate Cancer: Results of Intergroup 0159, Cancer and Leukemia Group B 9480 Journal of Clinical Oncology. 20: 3369-3375. PMID 12177096 DOI: 10.1200/Jco.2002.10.022  1
2002 Hinton S, Catalano P, Einhorn LH, Loehrer PJ, Kuzel T, Vaughn D, Wilding G. Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group Journal of Clinical Oncology. 20: 1859-1863. PMID 11919245 DOI: 10.1200/Jco.2002.07.158  1
2001 Thomas JP, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, Steele T, Marnocha R, Smith C, Smith S, MacDonald J, Wilding G, Bailey H. Phase I clinical and pharmacokinetic trial of irofulven. Cancer Chemotherapy and Pharmacology. 48: 467-72. PMID 11800027 DOI: 10.1007/S002800100365  1
2001 Wu S, Hafez G, Zhang J, Newton M, Chen A, Lange J, Wilding G. Identification of the prostate cancer micro-foci with chromosome 8p deletion at the tumor interface area by histopathological-FISH parallel examination. International Journal of Oncology. 19: 1143-1147. PMID 11713582 DOI: 10.3892/Ijo.19.6.1143  0.04
2001 Walczak J, Wood H, Wilding G, Williams T, Bishop CW, Carducci M. Prostate cancer prevention strategies using antiproliferative or differentiating agents. Urology. 57: 81-5. PMID 11295601 DOI: 10.1016/S0090-4295(00)00947-X  1
2001 Nelson WG, Wilding G. Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents. Urology. 57: 56-63. PMID 11295596 DOI: 10.1016/S0090-4295(00)00942-0  0.01
2001 Lieberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology. 57: 4-27. PMID 11295590 DOI: 10.1016/S0090-4295(00)00931-6  1
2000 Ochoa L, Hurwitz HI, Wilding G, Cohen D, Thomas JP, Schwartz G, Monroe P, Petros WP, Ertel VP, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky EK. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies Annals of Oncology. 11: 1313-1322. PMID 11106122 DOI: 10.1023/A:1008379802642  1
2000 Ryan CJ, Wilding G. Angionesis inhibitors: New agents in cancer therapy Drugs and Aging. 17: 249-255. PMID 11087003 DOI: 10.2165/00002512-200017040-00001  1
2000 Kasimis B, Wilding G, Kreis W, Feuerman M, Chang V, Hwang S, Steafather H, Cogswell J, Rae C, Blumenfrucht M. Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D2) prostate cancer. Cancer Investigation. 18: 602-608. PMID 11036467 DOI: 10.3109/07357900009032826  0.01
2000 Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma Journal of Clinical Oncology. 18: 2972-2980. PMID 10944130 DOI: 10.1200/Jco.2000.18.16.2972  1
2000 Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G. Phase II Study of Cisplatin and Paclitaxel in Advanced Carcinoma of the Urothelium: An Eastern Cooperative Oncology Group Study Journal of Clinical Oncology. 18: 1058-1061. PMID 10694557 DOI: 10.1200/Jco.2000.18.5.1058  1
1999 Witte RS, Lipsitz S, Goodman TL, Asbury RF, Wilding G, Strnad CM, Smith TJ, Haller DG. A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer. Investigational New Drugs. 17: 173-7. PMID 10638488 DOI: 10.1023/A:1006327418043  1
1999 Robins HI, Tutsch K, Katschinski DM, Jacobson E, Mehta M, Olsen M, Cohen JD, Tiggelaar CL, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G. Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer. Journal of Clinical Oncology. 17: 2922-2931. PMID 10561372 DOI: 10.1200/Jco.1999.17.9.2922  1
1999 Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Feierabend C, Robins HI, Spriggs DR, Wilding G. Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812). Investigational New Drugs. 17: 63-72. PMID 10555124 DOI: 10.1023/A:1006223100561  1
1999 Messing EM, Love RR, Tutsch KD, Verma AK, Douglas J, Pomplun M, Simsiman R, Wilding G. Low-dose difluoromethylornithine and polyamine levels in human prostate tissue Journal of the National Cancer Institute. 91: 1416-1417. PMID 10451448 DOI: 10.1093/Jnci/91.16.1416  1
1999 Robins HI, Katschinski DM, Longo W, Grosen E, Wilding G, Gillis W, Kraemer C, Tiggelaar CL, Rushing D, Stewart JA, Spriggs D, Love R, Arzoomanian RZ, Feierabend C, Alberti D, et al. A pilot study of melphalan, tumor necrosis factor-α and 41.8 °C whole-body hyperthermia Cancer Chemotherapy and Pharmacology. 43: 409-414. PMID 10100597 DOI: 10.1007/S002800050915  1
1999 Church D, Zhang Y, Rago R, Wilding G. Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice. Cancer Chemotherapy and Pharmacology. 43: 198-204. PMID 9923549 DOI: 10.1007/S002800050884  0.01
1999 Messing E, Manola J, Wilding G, Sarosdy M, Crawford D, Trump D. Immediate Hormonal Therapy Vs. Observation For Node Positive Prostate Cancer Following Radical Prostatectomy And Pelvic Lymphadenectomy: A Randomized Phase Iii Eastern Cooperative Oncology Group/Inter Group Trial The Journal of Urology. 175. DOI: 10.1097/00005392-199904010-00701  1
1998 Berlin JD, Alberti DB, Arzoomanian RZ, Feierabend CA, Simon KJ, Binger KA, Marnocha RM, Wilding G. A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Investigational New Drugs. 16: 325-330. PMID 10426665 DOI: 10.1023/A:1006242005837  1
1998 Pan HJ, Wilding G, Uno H, Inui S, Goldsmith L, Messing E, Chang C. Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine. 9: 39-43. PMID 9798729 DOI: 10.1385/Endo:9:1:39  0.08
1998 Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Bueschen AJ, Lowe BA. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer The New England Journal of Medicine. 339: 1036-1042. PMID 9761805 DOI: 10.1056/Nejm199810083391504  1
1998 Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells Proceedings of the National Academy of Sciences of the United States of America. 95: 7379-7384. PMID 9636157 DOI: 10.1073/Pnas.95.13.7379  0.01
1998 Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). American Journal of Clinical Oncology. 21: 171-6. PMID 9537206 DOI: 10.1097/00000421-199804000-00016  1
1998 Berlin J, Stewart JA, Storer B, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Wilding G. Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy. Journal of Clinical Oncology. 16: 1142-1149. PMID 9508201 DOI: 10.1200/Jco.1998.16.3.1142  1
1998 Wilding G. Prostate Cancer Marc S. Ernstoff, John A. Heaney, Richard E. Peschel, eds. Malden (MA): Blackwell Science, Inc., 1998. 211 pp., illus. $75. ISBN 0-6320-43172 Journal of the National Cancer Institute. 90: 1904-1904. DOI: 10.1093/Jnci/90.24.1904  0.01
1998 Wilding G. Testicular and Penile CancerMarc S. Ernstoff, John A. Heaney, Richard E. Peschel, eds. Malden (MA): Blackwell Science, Inc., 1998. 173 pp., illus. $85. ISBN 0-63204-319-9 Journal of the National Cancer Institute. 90: 1569-1569. DOI: 10.1093/Jnci/90.20.1569  0.01
1997 Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. Journal of the National Cancer Institute. 89: 1789-96. PMID 9392620 DOI: 10.1093/Jnci/89.23.1789  1
1997 Khorsand M, Lange J, Feun L, Clendeninn NJ, Collier M, Wilding G. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Investigational New Drugs. 15: 157-63. PMID 9220296 DOI: 10.1023/A:1005860806635  0.04
1997 Glen VL, Hutson PR, Kehrli NJ, Boothman DA, Wilding G. Quantitation of β-lapachone and 3-hydroxy-β-lapachone in human plasma samples by reversed-phase high-performance liquid chromatography Journal of Chromatography B: Biomedical Sciences and Applications. 692: 181-186. PMID 9187398 DOI: 10.1016/S0378-4347(96)00497-5  0.01
1997 Jeffers L, Church D, Basu H, Marton L, Wilding G. Effects of the polyamine analogues BE-4-4-4-4, BE-3-7-3, and BE-3-3-3 on the proliferation of three prostate cancer cell lines. Cancer Chemotherapy and Pharmacology. 40: 172-179. PMID 9182840 DOI: 10.1007/S002800050643  0.01
1997 Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. Journal of Clinical Oncology. 15: 781-789. PMID 9053505 DOI: 10.1200/Jco.1997.15.2.781  1
1997 Cleary JF, Arzoomanian R, Alberti D, Feierabend C, Storer B, Witt P, Carbone P, Wilding G. A phase I study of 5-fluorouracil, leucovorin and levamisole Cancer Chemotherapy and Pharmacology. 39: 300-306. PMID 9025770 DOI: 10.1007/S002800050576  1
1997 Mitchen J, Oberley T, Wilding G. Extended culturing of androgen-responsive human primary epithelial prostate cell isolates by continuous treatment with interstitial collagenase. The Prostate. 30: 7-19. PMID 9018330 DOI: 10.1002/(Sici)1097-0045(19970101)30:1<7::Aid-Pros2>3.0.Co;2-N  0.01
1997 Robins HI, Rushing D, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Spriggs D, Kraemer C, Gillis W, Feierabend C, Arzoomanian RZ, Longo W, Alberti D, d'Oleire F, Qu RP, ... Wilding G, et al. Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 158-64. PMID 8996137 DOI: 10.1200/Jco.1997.15.1.158  1
1997 Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-Antioxidant Shift Induced by Androgen Treatment of Human Prostate Carcinoma Cells Journal of the National Cancer Institute. 89: 40-48. PMID 8978405 DOI: 10.1093/Jnci/89.1.40  1
1995 Mitchen J, Bletzinger D, Rago R, Wilding G. Use of a DNA microfluorometric assay to measure proliferative response of mink lung cells to purified TGFβ and to TGFβ activity found in prostate cell conditioned medium In Vitro Cellular & Developmental Biology – Animal. 31: 692-697. PMID 8564080 DOI: 10.1007/Bf02634090  0.01
1995 Tomic S, Warner TF, Messing E, Wilding G. Penile merkel cell carcinoma Urology. 45: 1062-1065. PMID 7771012 DOI: 10.1016/S0090-4295(99)80134-4  0.01
1994 Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 194-205. PMID 8270977 DOI: 10.1200/Jco.1994.12.1.194  1
1994 Rago RP, Miles JM, Sufit RL, Spriggs DR, Wilding G. Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans. Cancer. 73: 1954-9. PMID 8137223 DOI: 10.1002/1097-0142(19940401)73:7<1954::Aid-Cncr2820730729>3.0.Co;2-H  1
1994 Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendeninn NJ, Wilding G. A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Investigational New Drugs. 12: 137-41. PMID 7860231 DOI: 10.1007/Bf00874444  1
1993 Ripple M, Mulcahy RT, Wilding G. Characteristics of the glutathione/glutathione-S-transferase detoxification system in melphalan resistant human prostate cancer cells The Journal of Urology. 150: 209-214. PMID 8510259 DOI: 10.1016/S0022-5347(17)35448-4  1
1993 Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, Pomplun M, Wilding G. Randomized phase I chemoprevention dose-seeking study of α-difluoromethylornithine Journal of the National Cancer Institute. 85: 732-737. PMID 8478959 DOI: 10.1093/Jnci/85.9.732  1
1993 Hutson PR, Tutsch K, Springgs D, Christian M, Rago R, Mutch R, Wilding G. Evidence of an absorption phase after short intravenous suramin infusions. Cancer Chemotherapy and Pharmacology. 31: 495-499. PMID 8453691 DOI: 10.1007/Bf00685042  1
1993 Love RR, Newcomb PA, Schiller JH, Wilding G, Stone HL. A comparison of knowledge and communication skill evaluations by written essay and oral examinations in preclinical medical students Journal of Cancer Education. 8: 123-128. PMID 8363938 DOI: 10.1080/08858199309528218  1
1993 Wilding G, Grindey G, Munshi N, Seitz D, Einhorn L. Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer Investigational New Drugs. 11: 203-205. PMID 8262732 DOI: 10.1007/Bf00874156  1
1993 Mitchen J, Rago R, Wilding G. Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates. The Prostate. 22: 75-89. PMID 7678932 DOI: 10.1002/Pros.2990220110  0.01
1992 Bailey H, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Grem JL, Spriggs DR. A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. Cancer Chemotherapy and Pharmacology. 30: 297-302. PMID 1643698 DOI: 10.1007/Bf00686299  1
1992 Bailey H, Kohler P, Tuttle R, Carbone PP, Hohneker JA, Clendeninn NJ, Wilding G. Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days. Investigational New Drugs. 10: 279-87. PMID 1487401 DOI: 10.1007/BF00944182  1
1992 Dreicer R, Wilding G. Steroid hormone agonists and antagonists in the treatment of cancer. Cancer Investigation. 10: 27-41. PMID 1370912 DOI: 10.3109/07357909209032786  1
1991 Goldstein D, O’Leary M, Mitchen J, Borden EC, Wilding G. Effects of Interferon βser and Transforming Growth Factor β on Prostatic Cell Lines The Journal of Urology. 146: 1173-1177. PMID 1895445 DOI: 10.1016/S0022-5347(17)38034-5  0.04
1990 Rage R, Mitchen J, Wilding G. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Analytical Biochemistry. 191: 31-34. PMID 1706565 DOI: 10.1016/0003-2697(90)90382-J  0.01
1985 Wilding G, Caruso R, Lawrence TS, Ostchega Y, Ballintine EJ, Young RC, Ozols RF. Retinal toxicity after high-dose cisplatin therapy. Journal of Clinical Oncology. 3: 1683-1689. PMID 4067616 DOI: 10.1200/Jco.1985.3.12.1683  0.01
Show low-probability matches.